Safety of Phage Therapy Evident in Cystic Fibrosis Patients With Persistent Pseudomonas aeruginosa Infection
BiomX Develops BX004-A, a Phage Therapy, for Cystic Fibrosis Patients with Pseudomonas Infections. A phase 1b/2a study presents promising results at IDWeek 2023.
CDC Publishes 2 Reports on Hepatitis Incidence Rates and Progress Towards 2025 Goals
Hepatitis C cases increased in 2021, while A and B decreased. The pandemic may have impacted the progress.
Majority of Patients With Long COVID Meet Criteria for POTS
A small study explored the connection between Postural Orthostatic Tachycardia Syndrome (POTS) and the COVID-19 condition.
Encouraging HBV Vaccine Data Presented at Liver Conference
Vaccitech, a biopharmaceutical company, has created a vaccine named VTP-300. They are currently showcasing positive initial results through a poster presentation at the ongoing European Association for the Study of the Liver (EASL) Congress 2023.
Sulbactam-Durlobactam FDA-Approved for Bacterial Pneumonia
Trade name Xacduro is an antibiotic meant to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by Acinetobacter baumannii.
Shortages Shown by Antibacterial Supply Patterns, Access Issues
Prescribers are presented with the optimal therapy challenges and achieving antibacterial stewardship.
Surveillance and Contact Precautions Result in Fewer MRSA Cases
With the focus of COVID-19, MRSA infections increased. How did the VA work to prevent this pathogen?
Candida auris: Using Public Health Messaging to Address Prevention
Despite the recent CDC warning and frightening media coverage, understanding which patients are at a higher risk of Candida auris is important too. The lead author of the recent CDC's study spoke to ICT's sister brand for further insights on the threat.
No Dapivirine Ring Safety Concerns in Third Trimester of Pregnancy
Dapivirine Vaginal Ring is a form of HIV prevention in cisgender women during pregnancy approved in several African countries and recommended by the WHO.
Clostridioides difficile: Examining Bezlotoxumab and Fecal Microbiota Transplantation
These treatments were reviewed in a real-world application to evaluate their effectiveness in preventing recurrences.
WHO Announced "Monkeypox" Will Now Be Known as "Mpox"
Because of negative connotations and stigma associated with the term "monkeypox," WHO will fade out the term and use "mpox" in its place.
Spikevax Booster’s Efficacy Falling Behind Omicron-Targeting Booster Candidates
No new safety concerns with this COVID-19 vaccine were reported.
Pfizer Announces Encouraging Data on RSV Vaccine for Pregnant Persons
Respiratory syncytial virus (RSV) can be deadly for newborns and young infants. The newest information from Pfizer about its RSCpreF investigational vaccine is promising for new mothers and infants through the first 90 days of life.
Recurrent C Difficile: Evaluating Patients’ Physical, Mental, Social Outlooks
The Clostridioides difficile Health-related Quality-of-Life Questionnaire responses demonstrated patients handled the situation better with specific investigational treatments.
CDC: Vaccine-Derived Polio Is Circulating in the United States
With this declaration the United States is put on a list of countries circulating the viruses, specifically noted in Rockland County, NY, where the vaccination rate is low and surrounding areas.
US Follows WHO: Monkeypox Is a Public Health Emergency
The declaration will allow more funds for control of and resources for the disease.
Monkeypox Declared Imminent Threat in San Francisco and New York State
With these declarations, the areas can use funds to help with preparedness and response to prevent the further spread of the disease.
Children 6 Months to 6 Years 1 Step Closer to a COVID-19 Vaccine
Moderna has filed for the first FDA Emergency Use Authorization for this age group.
Need a Mask or Not? Regulations Confuse Travelers
Masking during airline travel was halted yesterday by a federal judge, while other places, like Philadelphia, have re-implemented masking mandates.
Second Booster Shot Authorized by FDA for Patients 50 and Over
The FDA authorized a second booster for both Pfizer and Moderna vaccination recipients 4 months after first booster shot.
Moderna's Vaccine for Children 6 Months to 6 Years Meets Primary Endpoint in Phase 2/3
The dose is half the antigen amount for adults but with similar amount of titers.
EUA Submitted for Moderna COVID-19 Vaccine Amendment for Fourth Dose
The FDA approved the Moderna vaccine as a 2-dose primary series for persons 18 years of age and older earlier this year.
Pfizer CEO: Third Dose Is Good, But Fourth Is Needed For COVID-19
Pfizer CEO, Albert Bourla, said in nationally televised interview that it is necessary to fend off waning protection.
CDC Eases Mask Guidance
Face covering determinations will now be made based off hospitalizations, rather than case counts, among other metrics.
Sanofi and GSK to Seek Regulatory Authorization After “Robust Efficacy” Proven by COVID-19 Vaccine
This vaccine will add another alternative to the current vaccines on the market if approved in US and Europe.
Pfizer/BioNTech Vaccine Looks to Be Very Effective Against Omicron
Three doses ought to offer ample protection from infection, the companies say.
9-Point Plan to Combat Omicron Unveiled by Biden
Vaccinations continue to be the key strategy. The administration is looking at ways to encourage adults to get booster doses, as well as opening family clinics to get children vaccinated, and adults booster doses.
Pfizer/BioNTech COVID-19 Vaccine for 5 to 11 Year Olds OK’d by FDA Panel
The move is the first step in paving the way for younger children to get COVID-19 vaccines.
COVID-19 Vaccines for 5 to 11 Year Olds Appear on the Way
Enough of the Pfizer/BioNTech vaccine has been secured to offer vaccinations for everyone in this age group.
Moderna Wants FDA Approval for Pediatric COVID-19 Vaccine
The company reports that for fully vaccinated study participants aged 12-17 (2 doses administered) no cases of COVID-19 were reported.
2 Clarke Drive Cranbury, NJ 08512